ESAM-AS1: A Potential Drug Target and Biomarker (G101929340)

Target Name: ESAM-AS1

NCBI ID: G101929340

ESAM-AS1

Other Name(s): ESAM antisense RNA 1 | ESAM-AS1 variant 1

ESAM-AS1: A Potential Drug Target and Biomarker

ESAM-AS1 (ESAM antisense RNA 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the research on ESAM-AS1, its potential drug target status, and its potential as a biomarker for disease diagnosis and treatment.

Potential Drug Target

ESAM-AS1 has been shown to play a crucial role in various cellular processes, including cell signaling, DNA replication, and gene expression. Its expression has been found to be highly upregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that ESAM-AS1 can interact with several protein molecules, including the transcription factor ASXL1, which plays a role in regulating gene expression and cell signaling. Additionally, ESAM-AS1 has been shown to interact with the protein encoded by the gene IPF1, which is involved in the development and progression of various neurodegenerative diseases.

Given its involvement in cellular processes that are associated with the development and progression of various diseases, ESAM-AS1 has potential as a drug target for these conditions.

Potential Biomarker

In addition to its potential as a drug target, ESAM-AS1 has also been shown to have potential as a biomarker for disease diagnosis and treatment. Its expression has been found to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that ESAM-AS1 can be used as a biomarker for the diagnosis of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, ESAM-AS1 has been shown to be elevated in the blood samples of patients with cancer, which could potentially be used as a biomarker for cancer diagnosis and treatment.

ESAM-AS1 has also been shown to be involved in the regulation of cellular processes that are associated with the development and progression of autoimmune disorders. Given its potential as a biomarker for autoimmune disorders, ESAM-AS1 may have future potential as a therapy for these conditions.

Conclusion

In conclusion, ESAM-AS1 is a non-coding RNA molecule that has been shown to play a crucial role in various cellular processes that are associated with the development and progression of various diseases. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand its role in disease progression and its potential as a therapy.

Protein Name: ESAM Antisense RNA 1

The "ESAM-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESAM-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets